Research programme: TRINECTIN angiogenesis inhibitors - Compound Therapeutics

Drug Profile

Research programme: TRINECTIN angiogenesis inhibitors - Compound Therapeutics

Alternative Names: TRINECTIN angiogenesis inhibitors research programme - Compound Therapeutics

Latest Information Update: 23 Jan 2008

Price : $50

At a glance

  • Originator Adnexus Therapeutics
  • Class
  • Mechanism of Action Angiogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 23 Jan 2008 Discontinued - Preclinical for Cancer in USA (unspecified route)
  • 23 Jun 2006 No development reported - Preclinical for Cancer in USA (unspecified route)
  • 23 Jun 2006 Compound Therapeutics is now called Adnexus Therapeutics Inc.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top